133 related articles for article (PubMed ID: 27631358)
1. Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006.
Liu G; Unger ER; Hariri S; Steinau M; Markowitz LE
Sex Transm Dis; 2016 Oct; 43(10):633-6. PubMed ID: 27631358
[TBL] [Abstract][Full Text] [Related]
2. Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006.
Introcaso CE; Dunne EF; Hariri S; Panicker G; Unger ER; Markowitz LE
Sex Transm Infect; 2014 Sep; 90(6):505-8. PubMed ID: 24748563
[TBL] [Abstract][Full Text] [Related]
3. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
[TBL] [Abstract][Full Text] [Related]
4. Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey.
McClung NM; Lewis RM; Gargano JW; Querec T; Unger ER; Markowitz LE
J Adolesc Health; 2019 Dec; 65(6):715-722. PubMed ID: 31515134
[TBL] [Abstract][Full Text] [Related]
5. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.
Whittemore D; Ding L; Widdice LE; Brown DA; Bernstein DI; Franco EL; Kahn JA
J Womens Health (Larchmt); 2016 Nov; 25(11):1153-1158. PubMed ID: 27754751
[TBL] [Abstract][Full Text] [Related]
6. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty.
Niccolai LM; Russ C; Julian PJ; Hariri S; Sinard J; Meek JI; McBride V; Markowitz LE; Unger ER; Hadler JL; Sosa LE
Cancer; 2013 Aug; 119(16):3052-8. PubMed ID: 23661284
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
Lang Kuhs KA; Gonzalez P; Struijk L; Castro F; Hildesheim A; van Doorn LJ; Rodriguez AC; Schiffman M; Quint W; Lowy DR; Porras C; Delvecchio C; Katki HA; Jimenez S; Safaeian M; Schiller J; Solomon D; Wacholder S; Herrero R; Kreimer AR;
J Infect Dis; 2013 Nov; 208(10):1643-52. PubMed ID: 24014882
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Genital Human Papillomavirus by Age and Race/Ethnicity Among Males.
Berenson AB; Hirth JM; Chang M
Clin Infect Dis; 2021 Nov; 73(9):1625-1633. PubMed ID: 33983416
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
Coseo SE; Porras C; Dodd LE; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2011 Oct; 38(10):976-82. PubMed ID: 21934576
[TBL] [Abstract][Full Text] [Related]
11. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus (HPV) vaccination and oropharyngeal HPV in ethnically diverse, sexually active adolescents: community-based cross-sectional study.
Kerry-Barnard S; Beddows S; Reid F; Beckley-Hoelscher N; Soldan K; Panwar K; Seran C; Fleming C; Lesniewska A; Planche T; Williamson J; Hay P; Oakeshott P
Sex Transm Infect; 2021 Sep; 97(6):458-460. PubMed ID: 32883750
[TBL] [Abstract][Full Text] [Related]
13. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.
Markowitz LE; Hariri S; Lin C; Dunne EF; Steinau M; McQuillan G; Unger ER
J Infect Dis; 2013 Aug; 208(3):385-93. PubMed ID: 23785124
[TBL] [Abstract][Full Text] [Related]
14. Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012.
Berenson AB; Laz TH; Rahman M
J Infect Dis; 2016 Dec; 214(12):1961-1964. PubMed ID: 27821406
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?
Dunne EF; Sternberg M; Markowitz LE; McQuillan G; Swan D; Patel S; Unger ER
J Infect Dis; 2011 Aug; 204(4):562-5. PubMed ID: 21791658
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial.
Ferris DG; Brown DR; Giuliano AR; Myers E; Joura EA; Garland SM; Kjaer SK; Perez G; Saah A; Luxembourg A; Velicer C
Papillomavirus Res; 2020 Dec; 10():100202. PubMed ID: 32464334
[TBL] [Abstract][Full Text] [Related]
17. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.
Lehtinen T; Söderlund-Strand A; Petäjä T; Eriksson T; Jokiranta S; Natunen K; Dillner J; Lehtinen M
J Infect Dis; 2017 Nov; 216(8):966-968. PubMed ID: 28968844
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study.
Rahman S; Pierce Campbell CM; Rollison DE; Wang W; Waterboer T; Michel A; Pawlita M; Villa LL; Lazcano Ponce E; Borenstein AR; Giuliano AR
PLoS One; 2016; 11(11):e0167173. PubMed ID: 27902759
[TBL] [Abstract][Full Text] [Related]
20. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
